June 11, 2020

Acquisitions of companies involved in the medical devices business fall under the Italian foreign investment control

More than 2 months ago the Italian Government issued certain measures[1] with the purpose of expanding its power to veto or impose conditions on acquisitions of, or other transactions involving, Italian targets operating in certain strategic sectors.

Recently[2] the abovementioned measures have been converted into Law and have been partially amended in the conversion process.

One of the amendments consists of specifying that, on a temporary basis (i.e. until the issuance of the relevant implementing decrees), acquisitions of controlling stakes in Italian target companies operating in business of production, import and wholesale distribution of medical devices, medical/surgical devices and personal protective devices must be notified to the Italian Government under the foreign investment control regime.

We note that the same clarification has not been made with respect to those provisions (included in the same set of measures) aimed specifically at hindering the COVID-19 emergency which expand/strengthen significantly the Italian Government’s control power (providing duties to notify acquisitions of controlling stakes also by EU acquirors, etc.) until December 31, 2020.

For more information please see our article on “The Expansion of Italian Foreign Investment Control in the COVID-19 era” available at this link.

[1] Articles 15 and following of Law Decree no. 23 of April 8, 2020.

[2] By means of Law no. 40 of June 5, 2020.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
...
Read more
Our highly-ranked team of professionals will provide newsinsights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

Close
June 6, 2022
The National Coordination Centre for Ethics Committees published new draft agreements for conducting clinical trials on drugs and medical devices
April 27, 2022
EU Medical Device Coordination Group (MDCG) approves “Guidance” on the borderline between medical devices and medicinal products in order to support the uniform application of Regulation...
April 5, 2022
Electronic prescriptions: the current modalities of transmission from doctors to patients and from patients to pharmacies are extended until 31st December 2022
March 24, 2022
EU Medical Device Coordination Group (MDCG) approves “Guidance” on appropriate surveillance of devices covered by certificates according to the MD Directives, under the transitional prov...
March 21, 2022
Published Decree of Health Ministry identifying the ethics committees of national significance for clinical trials of medicinal products and medical devices
Search by...
Search
Follow us on
Follow us on